Pharmaceutical products: approx. 40%
Health products: approx. 30%
Dietary supplements: approx. 20%
Sales and logistics: approx. 10%

TOP 3 markets:
Indonesia: approx. 70%
Philippines: approx. 10%
Vietnam: approx. 8%

PT Kalbe Farma Tbk. generates the majority of its revenue from the sale of pharmaceutical products, followed by health products and dietary supplements. The Indonesian market is the most significant for the company, attributed to its strong local presence and comprehensive distribution network.

The Philippines and Vietnam are also important markets that have gained significance in recent years through strategic expansions and partnerships. Kalbe Farma has benefited from the growing demand for health products in these markets.

Production Sites: Indonesia (main site), Malaysia, Nigeria

PT Kalbe Farma Tbk. is one of the largest pharmaceutical companies in Indonesia and produces the majority of its products in the country. The main production site is located in Indonesia, where the company has several production facilities.

In addition, Kalbe Farma has established production capacities in Malaysia and Nigeria to better serve the regional market and strengthen its international presence. This strategic distribution of production sites enables the company to respond more efficiently to demand in different markets and optimize supply chains.

Revenue Growth: Estimated 10% (2025)

Strategic Focus Areas:

1. Product Diversification: PT Kalbe Farma Tbk. is focusing on expanding its product portfolio, especially in the health and nutritional supplements sector. This will be achieved through the introduction of new innovative products.

2. International Expansion: The company plans to strengthen its presence in international markets, particularly in Southeast Asia and Africa, to benefit from the growing health markets in these regions.

3. Investments in Research and Development: Kalbe Farma is increasing its investment in R&D to develop new therapeutic solutions and enhance existing products. This is intended to strengthen the company's competitiveness and innovation capabilities.

4. Digitalization and E-Commerce: The use of digital platforms and e-commerce channels is being expanded to improve customer access and optimize distribution.

These strategic initiatives aim to secure the company's future growth and strengthen its market leadership in the region.

Imported Raw Materials: Current data not available. Estimate based on 2023.

Main Supplier Countries: China, India, Germany

PT Kalbe Farma Tbk. is one of the leading pharmaceutical companies in Indonesia and imports various raw materials for the production of medicines and health products. Commonly imported materials include active pharmaceutical ingredients (APIs), packaging materials, and special chemicals.

China and India are significant suppliers of APIs, as these countries have strong pharmaceutical production capacities. Germany often supplies high-quality machinery and technologies for production as well as special pharmaceutical chemicals.

This import strategy enables Kalbe Farma to produce high-quality products while optimizing costs through sourcing from countries with competitive prices.

Market share in Indonesia: approx. 15% (2024, estimate)
R&D expenses: 2.5% of revenue (2023)
Revenue growth: 10% (2023)

PT Kalbe Farma Tbk. is one of the leading pharmaceutical companies in Indonesia and benefits from a significant market share in the domestic market. The company's competitive advantage lies in its strong brand presence and a wide product portfolio that includes both prescription and over-the-counter medications.

The company continuously invests in research and development, as evidenced by the R&D expenses of 2.5% of revenue in 2023. These investments enable Kalbe Farma to develop and launch innovative products, enhancing its competitiveness.

Additionally, the revenue growth of 10% in 2023 contributes to financial stability and the ability to expand into new markets. The focus on local and regional markets, as well as compliance with regulatory requirements, provides the company with another advantage over international competitors.

Institutional Investor Share: approximately 45% (estimated for 2025)

Insider Purchases/Sales: No specific current data available

The institutional investor share in PT Kalbe Farma Tbk. is estimated to be around 45%. This estimate is based on historical data and typical industry patterns for large publicly traded companies in Indonesia.

There is no specific current data available on insider purchases or sales. Such transactions are often disclosed in annual reports or through regulatory filings. It is advisable to consult the latest company reports or stock exchange announcements for detailed information.

Market share of PT Kalbe Farma Tbk: 18% (2025, estimated)

Top competitors and their market shares:

1. PT Kalbe Farma Tbk: 18%
2. PT Kimia Farma Tbk: 15%
3. PT Bio Farma: 12%
4. PT Indofarma Tbk: 10%
5. PT Phapros Tbk: 8%
6. Sanbe Farma: 7%
7. Dexa Medica: 6%
8. PT Soho Global Health: 5%
9. PT Tempo Scan Pacific Tbk: 4%
10. PT Darya-Varia Laboratoria Tbk: 3%

Moat of PT Kalbe Farma Tbk:

PT Kalbe Farma Tbk has a significant moat, mainly supported by its strong brand recognition, wide product portfolio, and extensive distribution networks. The company benefits from its long-standing market presence and a high level of consumer trust.

Compared to competitors, Kalbe Farma has an advantage in research and development, leading to innovative products. Additionally, the company has strengthened its market position through strategic partnerships and acquisitions.

However, some competitors, especially PT Kimia Farma Tbk and PT Bio Farma, are catching up with government support and investments in new technologies. These companies could expand their market shares in the coming years, intensifying competition.

Overall, PT Kalbe Farma Tbk currently has a solid moat but needs to continuously invest in innovation and efficiency to maintain its leading position.

Revenue growth: 8.5% (2024) Profit growth: 7.2% (2024) Market share in the healthcare sector of Indonesia: 15% (2024)

PT Kalbe Farma Tbk. is one of the leading companies in the healthcare sector in Indonesia and demonstrates solid revenue and profit growth. In 2024, the company recorded a revenue growth of 8.5% and a profit growth of 7.2%, indicating strong demand for its products and services.

The company benefits from its strong market position and a diversified product portfolio ranging from pharmaceutical products to health beverages. With a market share of 15% in the Indonesian healthcare sector, Kalbe Farma is well positioned to benefit from the growing healthcare demand in the region.

Furthermore, Kalbe Farma continuously invests in research and development to bring innovative products to the market, which could lead to a competitive advantage in the long term. Given these factors, the stock of PT Kalbe Farma Tbk. could be an attractive investment for investors interested in a stable and growth-oriented company in the healthcare sector.

Dividend Yield: 2.5% (2024) Dividend History: Consistent payout over the last 5 years

PT Kalbe Farma Tbk. has pursued a consistent dividend policy in recent years. The company has regularly distributed dividends, indicating a reliable payout policy.

The dividend yield was recently around 2.5%, which can be considered stable compared to other companies in the industry. This continuity shows that Kalbe Farma is committed to providing shareholders with a regular return, which can be attractive to investors who value dividend payments.